Head & Neck

Advanced:

CIRB #H-29284/RTOG #R0920: A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab For Locally-Advanced Resected Head and Neck Cancer

IRB #H-33141/CTSU #E3311: A Phase II Randomized Trial of Transoral Surgical Resection followed by Low-dose or Standard-dose IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer (pending IRB approval)

IRB #H-32666/RTOG #R1221: A Randomized Ph. II Trial of Transoral Endoscopic Head And Neck Surgery followed by Risk-Based IMRT and Weekly Cisplatin versus IMRT and Weekly Cisplatin for HPV Negative Oropharynx Cancer (pending IRB approval)

High Risk:

CIRB #H-32379/RTOG #R1216: Randomized Phase II/III Trial of Surgery and Postoperative Radiation Delivered With Concurrent Cisplatin versus Docetaxel versus Docetaxel and Cetuximab for High-Risk Squamous Cell Cancer of the Head and Neck Salivary Gland Tumors:

IRB #H-32124/RTOG# R1008: A Randomized Phase II Study of Adjuvant Concurrent Radiation and Chemotherapy versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors

Nasopharyngeal:

CIRB #H-33148/NRG# HN001: Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA) (pending IRB approval)

Primary teaching affiliate
of BU School of Medicine